ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL
Sudharshan Eashtiraj1, Yi Yu1, Ronald E. Savage1, Giovanni Abbadesa1, Sean D. Reiff1, Jennifer A. Woyach2, Amy J. Johnson2, Brian Schwartz3
1ArQule, Inc., One Wall Street, Burlington, MA, 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

**BACKGROUND**
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL

**RESULTS**
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL

**MATERIALS AND METHODS**
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL

**CONCLUSIONS**
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL

**REFERENCES**
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL